Replies to post #9921 on CSMG Technologies, Inc (fka CTGI)

[rocketeer357]

I think Don knows exactly when that filing date will come. If you listen to the interview, he hesitates slighty when he's talking about the FDA submission date, continuing to say, "in the very near future."

Here's hoping that with his understated style, we can expect a big PR within 2 weeks.

[sojourner]

Excerpts from today's Robbins interview hosted by StockWire:

http://www.stockwire.com/content/view/254/153/

"...Empire Financial Group currently raising additional $3 million to $5 million in a private offering."

"We have finished prototype duct and vessel sealer for the tissue bonding, our first product to bring to market out of about 12 products we have identified with this technology.... We have hired and signed contracts with Stellar Tech to develop the commercial electro-generator, VIR to design instruments and Ventrex to manufacture instruments."

"...in the next very short time we will be filing US FDA 510(k)..."

"...toward end of the year we should have first commercial product rolling out the door.... We'll be bringing on a group of people to market (the product). This may be in the form of large companies marketing our product, us (sic) going to direct distributors or licensing part of the product out. We have identified 12 different procedures which gives us 12 different opportunities in different segments of the market..."

"We're going after the sutures and staples market... That market is over $4 billion worldwide."

Robbins noted that CTUM's chief competitors are US Surgical (80% of staples market) and Johnson & Johnson (controls sutures market).

"We are able to re-connect living tissue without the use of sutures or staples, and we are able to get very good burst strengths."

http://www.stockwire.com/content/view/254/153/

About CTUM: Consortium Service Management Group, Inc., doing business as CSMG Technologies, Inc., operates as a technology management company. CSMG and its subsidiaries engage in financing, owning, developing, managing, patenting, licensing, and marketing technologies primarily in Ukraine.

The company and its subsidiaries engage in the ownership, development, licensing, and marketing of technologies, which primarily include the live tissue bonding technology and carbon dioxide separator technology.

Its live tissue bonding technology focuses on bonding living soft biological tissue using specifically designed surgical tools, which eliminates the need for sutures, staples, sealants, or glues.

[emilson]

Thank you ninjaturtle that was a good interview. I which he would have touched on very little loss of blood and no infection.